48,890 results match your criteria Multiple Myeloma


F-FDG PET/CT in multiple myeloma: critical insights and future directions.

Eur J Nucl Med Mol Imaging 2019 Feb 15. Epub 2019 Feb 15.

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04279-7DOI Listing
February 2019

Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.

Leukemia 2019 Feb 15. Epub 2019 Feb 15.

Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Aberrant activation of Wnt/β-catenin signaling plays a central role in the pathogenesis of a wide variety of malignancies and is typically caused by mutations in core Wnt pathway components driving constitutive, ligand-independent signaling. In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wnt pathway activity. Recent studies indicate that this activation is caused by genetic and epigenetic lesions of Wnt regulatory components, sensitizing MM cells to autocrine Wnt ligands and paracrine Wnts emanating from the bone marrow niche. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0404-1DOI Listing
February 2019

Regions of homozygosity as risk factors for multiple myeloma.

Ann Hum Genet 2019 Feb 15. Epub 2019 Feb 15.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

Genomic regions of homozygosity (ROH), detectable in outbred populations, have been implicated as determinants of inherited risk. To examine whether ROH is associated with risk of multiple myeloma (MM), we performed whole-genome homozygosity analysis using single-nucleotide polymorphism genotype data from 2,282 MM cases and 5,197 controls, with replication in an additional 878 MM cases and 7,083 controls. Globally, the distribution of ROH between cases and controls was not significantly different. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ahg.12304DOI Listing
February 2019

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15800DOI Listing
February 2019
1 Read

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma.

Front Pharmacol 2019 31;10:45. Epub 2019 Jan 31.

Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China.

To investigate the prognostic value of lncRNA NR_046683 in multiple myeloma (MM). High-throughput lncRNA array was combined with bioinformatics techniques to screen differentially expressed lncRNA in MM. qRT-PCR was adopted to determine the expression of target lncRNAs in MM patients and controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365438PMC
January 2019

Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

J Am Soc Nephrol 2019 Feb 14. Epub 2019 Feb 14.

School of Public Health, University of Sydney, Sydney, Australia.

Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation.

Methods: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018090906DOI Listing
February 2019
9.343 Impact Factor

miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma.

Mol Ther 2019 Jan 24. Epub 2019 Jan 24.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China. Electronic address:

Inherent or acquired resistance to chemotherapeutic drugs is still an obstacle for the treatment of multiple myeloma (MM). MicroRNA dysregulation is related to the development of chemoresistance in cancers. However, its role in chemoresistance of MM is largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2019.01.012DOI Listing
January 2019

Epidemiology of Plasma Cell Leukemia in the Czech Republic.

Klin Onkol 2019 ;32(1):47-51

Background: Plasma cell leukemia (PCL) is a rare but most aggressive form of monoclonal gammopathies. PCL is characterized by the presence of clonal plasma cells in peripheral blood. There are two forms of PCL - primary which presents de novo in patients with no evidence of previous multiple myeloma and secondary which is a leukemic transformation of relapsed or refractory dis-ease in patients with previously recognized multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14735/amko2019DOI Listing
January 2019

Plasma Cell Leukemia -  the Forgotten Dis-ease.

Klin Onkol 2019 ;32(1):40-46

Background: Plasma cell leukemia (PCL) is a rare dis-ease and possibly the most aggressive form of monoclonal gammopathy. It is classified into two forms -  primary PCL that occurs without a previously identifiable multiple myeloma stage, and secondary PCL that develops from previously dia-gnosed multiple myeloma. These two forms have different cytogenetic and molecular profiles, but both forms have an aggressive clinical course. Read More

View Article

Download full-text PDF

Source
January 2019

Actinomyces Orbital Osteomyelitis in the Setting of Multiple Myeloma and Bisphosphonate-Related Osteonecrosis.

J Neuroophthalmol 2019 Mar;39(1):120-121

Department of Ophthalmology, Saint Louis University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNO.0000000000000729DOI Listing

The experiences and needs of primary family caregivers of patients with multiple myeloma: A qualitative analysis.

Palliat Med 2019 Feb 14:269216319830017. Epub 2019 Feb 14.

6 Department of Nursing, Escola Universitària d'Infermeria Gimbernat, Barcelona, Spain.

Background:: Family caregivers play a key role in the lives of patients with multiple myeloma. However, very little is known about the impact that the disease (its diagnosis, course and prognosis) has on the main family caregiver.

Aim:: To achieve a deeper understanding of the lived experience of individuals who are the primary caregiver of a relative with multiple myeloma and to shed light on their needs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269216319830017DOI Listing
February 2019

Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?

Turk J Med Sci 2019 Feb 11;49(1):265-271. Epub 2019 Feb 11.

Background/aim: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyte attack. Our goal was to determine the PD-1 and PD-L2 expression rates of various hematologic malignancies, and evaluate whether PD-1 and PD-L2 expressions have an impact on prognosis. Read More

View Article

Download full-text PDF

Source
http://online.journals.tubitak.gov.tr/openAcceptedDocument.h
Publisher Site
http://dx.doi.org/10.3906/sag-1706-194DOI Listing
February 2019
1 Read

Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines.

Cureus 2018 Dec 1;10(12):e3669. Epub 2018 Dec 1.

Oncology, University of Louisville School of Medicine, Louisville, USA.

Multiple myeloma (MM) is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. With median age of 66 at the time of presentation, multiple myeloma is predominantly a disease of the elderly. The availability of new combination regimens and the enhanced safety of autologous hematopoietic stem cell transplant has increased the treatment options for elderly patients with multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3669DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364954PMC
December 2018

Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.

Epigenomes 2018 Sep 3;2(3). Epub 2018 Sep 3.

Division of Hematology and Oncology, Department of Medicine, University of Florida Health Cancer Center, University of Florida, Gainesville, FL 32610, USA;

The enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of the polycomb repressive complex 2 (PRC2) that exerts important functions during normal development as well as disease. PRC2 through EZH2 tri-methylates histone H3 lysine tail residue 27 (H3K27me3), a modification associated with repression of gene expression programs related to stem cell self-renewal, cell cycle, cell differentiation, and cellular transformation. EZH2 is deregulated and subjected to gain of function or loss of function mutations, and hence functions as an oncogene or tumor suppressor gene in a context-dependent manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/epigenomes2030016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370027PMC
September 2018

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

Leukemia 2019 Feb 13. Epub 2019 Feb 13.

Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM patients remains poor and demands the identification of novel agents to potentiate the therapeutic effect of IMiDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0403-2DOI Listing
February 2019
2 Reads

Myeloma bone disease: from biology findings to treatment approaches.

Blood 2019 Feb 13. Epub 2019 Feb 13.

Department of Clinical Therapeutics, Alexandra General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors they participate in increased osteoclast activity, decreased osteoblast function and immunosuppressed marrow microenvironment that deregulate bone turnover and result in bone loss and skeletal-related events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-852459DOI Listing
February 2019

Modulation of the ATM/autophagy pathway by a G-quadruplex ligand tips the balance between senescence and apoptosis in cancer cells.

Nucleic Acids Res 2019 Feb 13. Epub 2019 Feb 13.

Institut Bergonié, Université de Bordeaux, INSERM U1218, F-33076 Bordeaux, France.

G-quadruplex ligands exert their antiproliferative effects through telomere-dependent and telomere-independent mechanisms, but the inter-relationships among autophagy, cell growth arrest and cell death induced by these ligands remain largely unexplored. Here, we demonstrate that the G-quadruplex ligand 20A causes growth arrest of cancer cells in culture and in a HeLa cell xenografted mouse model. This response is associated with the induction of senescence and apoptosis. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/nar/advance-article/doi/10.1093/nar
Publisher Site
http://dx.doi.org/10.1093/nar/gkz095DOI Listing
February 2019
1 Read

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.

PLoS One 2019 13;14(2):e0211927. Epub 2019 Feb 13.

Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infectious complications is unclear. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211927PLOS
February 2019

Pityriasis amiantacea following bone marrow transplant.

Cutis 2019 Jan;103(1):46-50

San Diego Family Dermatology, National City, California; Family Health Center of San Diego, California; Scripps Mercy Hospital Chula Vista, California; and the College of Osteopathic Medicine, Touro University California, Vallejo, USA.

Pityriasis amiantacea (PA) is a hair disorder characterized by matting of multiple hair shafts, typically occurring as an idiopathic condition. A 67-year-old woman with multiple myeloma who developed PA following a bone marrow transplant with melphalan conditioning is described.She noted initial changes in scalp hair regrowth 4 weeks posttransplant. Read More

View Article

Download full-text PDF

Source
January 2019

Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia.

Sci Rep 2019 Feb 12;9(1):1875. Epub 2019 Feb 12.

Department of Pediatric Oncology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, The Netherlands.

The FGF receptor signaling pathway is recurrently involved in the leukemogenic processes. Oncogenic fusions of FGFR1 with various fusion partners were described in myeloid proliferative neoplasms, and overexpression and mutations of FGFR3 are common in multiple myeloma. In addition, fibroblast growth factors are abundant in the bone marrow, and they were shown to enhance the survival of acute myeloid leukemia cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38169-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372586PMC
February 2019

Cellular immunotherapy in multiple myeloma.

Korean J Intern Med 2019 Feb 15. Epub 2019 Feb 15.

Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Hwasun, Korea.

In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2018.325DOI Listing
February 2019

Body size and obesity during adulthood, and risk of lympho-hematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.

Ann Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Epidemiology and Biostatistics, Imperial College, London, United Kingdom.

Background: To summarise the evidence on the associations between body mass index (BMI) and BMI in early adulthood, height, waist circumference (WC) and waist to hip ratio (WHR), and risk of lympho-hematopoietic cancers.

Method: We conducted a meta-analysis of prospective studies and identified relevant studies published up to December 2017 by searching PubMed. A random effects model was used to calculate dose-response summary relative risks (RRs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz045DOI Listing
February 2019
1 Read

Evaluation of peripheral blood mononuclear cell collection by leukapheresis.

Transfusion 2019 Feb 12. Epub 2019 Feb 12.

Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Background: Adoptive immunotherapy using engineered lymphocytes has shown promising results in treating cancers even in patients who have failed other treatments. As the first essential step, the number of peripheral mononuclear cell (MNC) collection procedures is rapidly increasing. In this retrospective study, we reviewed the collection results to determine factors that affect MNC collection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15186DOI Listing
February 2019

Autologous lymphocyte infusion supports tumor antigen vaccine-induced immunity in autologous stem cell transplant for multiple myeloma.

Cancer Immunol Res 2019 Feb 11. Epub 2019 Feb 11.

Multiple Myeloma Program, Tisch Cancer Insititute, Icahn School of Medicine at Mount Sinai

Autologous stem cell transplant (autoSCT), the standard consolidation therapy for multiple myeloma, improves disease-free survival but is not curative. This could be an ideal setting for immunologic therapy. However, the immune milieu is impaired after autoSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0198DOI Listing
February 2019
1 Read

PKP/PVP combine chemotherapy in the treatment of multiple myeloma patients with vertebral pathological fractures: minimum 3-year follow-up of 108 cases.

J Orthop Surg Res 2019 Feb 11;14(1):42. Epub 2019 Feb 11.

Department of Orthopaedics, Beijing Chao-Yang Hospital, Capital Medical University, No.8 Gongren Tiyuguan Nanlu, Chaoyang district, Beijing, China.

Background: Multiple myeloma (MM) is a blood system malignant tumor, which often leads to osteolytic bone destruction, and the vertebral column is the primary site of involvement. However, the efficacy and prognosis of percutaneous kyphoplasty/vertebroplasty (PKP/PVP) for simple vertebral pathological fractures in patients with multiple myeloma are not yet unified. The primary objective of this study was to investigate the efficacy and prognosis of PKP/PVP in the treatment of multiple myeloma patients with vertebral pathological fractures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13018-019-1078-0DOI Listing
February 2019

Very unusual expression of multiple aberrant T-cell markers in plasmablastic plasma cell myeloma.

Int J Lab Hematol 2019 Feb 11. Epub 2019 Feb 11.

Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12985DOI Listing
February 2019

Acromegaly associated with GIST, non-small cell lung cancer, clear cell renal cancer, myeloma multiplex, medulla oblongata tumor, adrenal adenoma and follicular thyroid nodules.

Endokrynol Pol 2019 Feb 11. Epub 2019 Feb 11.

Dept. of Endocrinology, Diabetes and Isotope Therapy, Medical University Wroclaw, Pasteura 4, 50-367 Wrocłąw, Poland.

Background: Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumor development and growth.

Case Presentation: A 68-year old woman was diagnosed with acromegaly due to typical clinical and hormonal characteristics. While a contrast-enhanced MRI at diagnosis did not reveal a pituitary adenoma, a 5 mm lesion was identified on repeat scanning 13 months later. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/EP.a2019.0005DOI Listing
February 2019
5 Reads

Modeling the Effects of Multiple Myeloma on Kidney Function.

Sci Rep 2019 Feb 11;9(1):1726. Epub 2019 Feb 11.

University of Nebraska Medical Center, Division of Oncology & Hematology, Omaha, 68198, USA.

Multiple myeloma (MM), a plasma cell cancer, is associated with many health challenges, including damage to the kidney by tubulointerstitial fibrosis. We develop a mathematical model which captures the qualitative behavior of the cell and protein populations involved. Specifically, we model the interaction between cells in the proximal tubule of the kidney, free light chains, renal fibroblasts, and myeloma cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38129-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370764PMC
February 2019

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.

Blood Cancer J 2019 Feb 11;9(2):19. Epub 2019 Feb 11.

Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA.

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-220, but not to Bortezomib. In three HMLCs (MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0173-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370766PMC
February 2019

Health benefits of resveratrol: Evidence from clinical studies.

Med Res Rev 2019 Feb 11. Epub 2019 Feb 11.

Laboratory for Translational Cancer Research, Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India.

Resveratrol is a polyphenolic nutraceutical that exhibits pleiotropic activities in human subjects. The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical trials currently ongoing. Resveretrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes mellitus, obesity, colorectal cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Alzheimer's disease, stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/med.21565DOI Listing
February 2019

Small Molecule Inhibitors of the Proteasome's Regulatory Particle.

Chembiochem 2019 Feb 10. Epub 2019 Feb 10.

Purdue University, Medicinal Chemistry, 575 W. Stadium Ave, RHPH 506A, 47907, West Lafayette, UNITED STATES.

Cells need to consistently synthesize and degrade proteins. Maintaining a balanced level of protein in the cell requires a carefully controlled system and significant energy. Degradation of unwanted or damaged proteins into smaller peptide units can be accomplished by the proteasome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbic.201900017DOI Listing
February 2019
1 Read

Phase II study of carfilzomib and dexamethasone (Kd) therapy for newly diagnosed multiple myeloma.

Am J Hematol 2019 Feb 10. Epub 2019 Feb 10.

Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.

Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase 2 study of 72 patients with NDMM to evaluate the efficacy and tolerability of Kd induction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25435DOI Listing
February 2019
1 Read
3.798 Impact Factor

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Ann Transl Med 2018 Dec;6(Suppl 2):S93

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.11.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330615PMC
December 2018

Postoperative Spine Infection - Postoperative MRSA Infection in a Wrongly Diagnosed Case of Spine Trauma.

Authors:
Suresh Pillai

J Orthop Case Rep 2018 Sep-Oct;8(5):54-56

Department of Spine, Aster MIMS Hospital, Govindapurasam, Calicut, Kerala, India.

Introduction: Pathological fractures resulting from trivial trauma may be overlooked, especially, when it is after a road traffic accident.

Case Report: A 56-year-old male was operated elsewhere for burst fracture L3 vertebra following a trivial road traffic accident. Due to the persistence of symptoms, he was reevaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13107/jocr.2250-0685.1210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367292PMC
February 2019

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma.

Chonnam Med J 2019 Jan 25;55(1):25-30. Epub 2019 Jan 25.

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.

This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4068/cmj.2019.55.1.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351330PMC
January 2019
1 Read

BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner.

Transl Res 2019 Jan 23. Epub 2019 Jan 23.

Oncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel; Research Authority, Meir Medical Center, Kfar Saba, Israel. Electronic address:

Multiple myeloma (MM) malignant plasma cells accumulate in the bone marrow (BM) where their interaction with the microenvironment promotes disease progression and drug resistance. Previously, we have shown that MM cells cocultured with BM-mesenchymal stem cells (MSCs) comodulated cells' phenotype in a MAPKs/translation initiation (TI)-dependent manner. Dissection of the coculture model showed that BM-MSCs secretomes and microvesicles (MVs) participate in this crosstalk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trsl.2019.01.003DOI Listing
January 2019

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Lancet Haematol 2019 Feb 6. Epub 2019 Feb 6.

Department of Haematology, Newcastle University, Newcastle-upon-Tyne, UK.

Background: Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict overall survival in patients with multiple myeloma who were ineligible for stem-cell transplantation.

Methods: We used patient data from two randomised controlled trials done in patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation (the NCRI Myeloma XI study [NCRI-XI, n=1852] and the MRC Myeloma IX study [MRC-IX, n=520]), to develop the UK Myeloma Research Alliance Risk Profile (MRP) for overall survival. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183022
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30220-5DOI Listing
February 2019
2 Reads

Frailty in multiple myeloma: the need for harmony to prevent doing harm.

Lancet Haematol 2019 Feb 6. Epub 2019 Feb 6.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30011-0DOI Listing
February 2019

Breast cancer after multiple myeloma treatment.

Authors:
Ahmet Gulmez

Curr Probl Cancer 2019 Feb 1. Epub 2019 Feb 1.

Inonu Univercity Turgut Ozal Medical Center, Malatya/Türkiye, Malatya, Turkey. Electronic address:

Breast cancer is the most common cancer in women. In addition, it is the second leading cause of death after lung cancer. The prevalence of epidemiological studies in previous studies is 22%-26%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2019.01.004DOI Listing
February 2019

[Etiologyical Analysis of 133 Patients with Elderly Macrocytic Anemia and Diagnostic Significance of Laboratory Tests].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):202-207

Department of Hematology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning Province, China.

Objective: To study the etiology of macrocytic anemia in elderly patients and to evaluate the diagnostic significance of laborotory tests.

Methods: 133 elderly macrocytic anemia patients, whose age>60 years old, hemoglobin<100 g/L, mean red cell volume(MCV)>100 fL, and bone marrow cell test was performed, and these patients were grouped according to diseases, and the bilirubin, lactate dehydrogenase, folic acid, vit B12 and serum ferritin were tested, then the results of tests were compared and analyzed.

Results: The majority of the cases were diagnosed as megaloblastic anemia (MA), myelodysplasia syndrome (MDS), acute leukemia/multiple myeloma (AL/MM) and hemolytic anemia (HA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.033DOI Listing
February 2019
1 Read

[Expression and Clinical Significance of C/EBPα Gene in Elderly Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):123-128

Department of Hematology, Henan Province People's Hospital, Zhengzhou 450003, Henan Province,China.

Objective: To investigate the expression of C/EBPα gene in elderly patients with multiple myeloma (MM) and its prognostic significance.

Methods: Sixty-nine olderly patients with multiple myeloma (MM) treated in our hospital from February 2015 to October 2017 were selected and enrolled in the MM group, 38 healthy persons received physical examination were selected and enrolled in the control group. The bone marrow of 2 groups was collected and the mononuclear cells were isolated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.020DOI Listing
February 2019
2 Reads

[Prognostic Value of Red Blood Cell Distribution Width in Senile Potients with Non-trans planted Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):115-122

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.

Objective: To investigate the prognostic value of red blood cell distribution width (RDW) in senile patients with non-transplanted multiple myeloma (MM).

Methods: The RDW and clinical parameters such as β-2 microglobulin, creatiain, LDH and so on at diagnosis of 99 newly diagnosed senile MM patients were analysed retrospectively. The 99 patients were treated with chemotherapeutic regimens with or without bertezomib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.019DOI Listing
February 2019

[Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):110-114

Department of Hematology, Zhabei Branch of Changzheng Hospital, The Second Military Medical University, Shanghai 200070, China.E-mail:

Objective: To evaluate the prognostic value of R-ISS staging system in patients with newly diagnosed multiple myeloma (NDMM).

Methods: The Chinical data of 412 patients with NDMM in our hospital from May 2010 to May 2016 were retrospectively analyzed. All the patients received conventional chemotherapy or thalidomide or bortezomib-based chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.018DOI Listing
February 2019
1 Read

[Clinical Analysis of Serum Calcium Level in 86 Cases of Newly Diagnosed Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):104-109

Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.E-mail:

Objective: To investigate the serum calcium level in 86 patients with newly diagnosed multiple myeloma (MM) and its correlation with clinical features.

Methods: The clinical data of 86 patients with newly diagnosed multiple myeloma in our hospital from 2009 to 2016 were retrospectively analyed. Clinical data of sex, age, hemoglobin, albumin, globulin, creatinine, uric acid, serum phosphorus, β2-microglobulin, immunophenotyping and disease staging were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.017DOI Listing
February 2019
1 Read

[Life Quality and Its Related Factors of Patients with Multiple Myeloma during Maintenance Therapy].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):96-103

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.E-mail:

Objective: To evaluate the quality of life (QOL) on patients with multiple myeloma(MM) during maintenance therapy and to explore the related factors important for QOL.

Methods: The demography, clinical and laboratorial data of 66 MM patients during maintenance therapy were collected and explored by using a cross-sectional question naire(EORTC QLQ C30 V 3.0). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.016DOI Listing
February 2019
1 Read

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

Blood 2019 Feb 8. Epub 2019 Feb 8.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;

Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings but drug resistance is an emerging challenge, and this has prompted interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attractive target is the E1 ubiquitin activating enzyme (UAE), and we therefore evaluated the activity of TAK-243, a novel and specific UAE inhibitor. TAK-243 potently suppressed myeloma cell line growth, induced apoptosis, and activated caspases while decreasing the abundance of ubiquitin-protein conjugates. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-06
Publisher Site
http://dx.doi.org/10.1182/blood-2018-06-859686DOI Listing
February 2019
1 Read